Purpose of review Testicular germ cell tumors (TGCTs) are a model for curable cancer because of exquisite chemosensitivity and incorporation of multimodal therapy. Nevertheless, our ability to predict metastases in early-stage disease and responders to chemotherapy in advanced disease is limited. Treatment options for cisplatinresistant disease are sparse. A further understanding of TGCT biology may allow for more precise patient counseling and identify novel therapies in patients with cisplatin-resistant disease.
INTRODUCTION
Testicular germ cell tumors (TGCTs) represent the most common solid malignancy in young men [1] . TGCTs are divided broadly into seminoma and nonseminoma (NSGCT) as these distinctions inform management decisions, treatment options, and prognosis. Even when presenting in an advanced setting, testicular cancer represents a rare oncologic success story: the 5-year overall survival (OS) rate is over 80% even among patients with metastatic disease with fewer than 400 deaths from TGCT in the United States estimated in 2016 [1, 2] .
The optimal treatment for many patients with TGCT is unknown given the high cancer-specific survival rates and relative young age at presentation for most men diagnosed with testicular cancer [3] , which highlights the need to minimize treatment morbidity when maximizing cancer control. For example, stage I TGCTs can be effectively managed with surveillance, chemotherapy, and radiation (for seminoma) or retroperitoneal lymph node dissection (for NSGCT). With surveillance, there is a subsequent need for intervention in about 20% of cases, and conversely the disadvantage of immediate intervention is potential overtreatment in 80% of cases along with attendant risks including surgical risks, infertility, organ damage, and future malignancies [4] . In the advanced setting, up to 30% of advanced germ cell tumors exhibit cisplatin-resistance and require salvage treatment, which is effective less than 50% of the time [5] . Significant uncertainty remains regarding when to perform postchemotherapy lymph node dissection and decisions about optimal salvage chemotherapy regimens in the refractory clinical state.
Improving upon patient outcomes requires better understanding of the molecular and genetic basis of these tumors. TGCTs often represent a mix of histologies, which make genetic correlatives with a particular histology difficult, necessitating careful microdissection [6] . Furthermore, the degree of intratumoral heterogeneity is not yet well understood in TGCT, which complicates the implementation of precision medicine for this disease [7] .
TESTICULAR GERM CELL TUMOR DEVELOPMENT
Identified risk factors for TGCT include cryptorchidism, family history, previous germ cell tumor, subfertility, and disorders of sexual differentiation, yet the majority of TGCTs occur spontaneously without known genetic loci of susceptibility [8, 9] . Recent genomic studies suggest heritability of TGCT at 48.9%, with known single nucleotide polymorphisms (SNPs) representing only 9.1% of total heritability [10 && ]. Several gene loci were identified using genome-wide association studies (GWAS) that appear related to TGCT predisposition, including KITLG, SPRY4, BAK1, DMRT1, TERT, and ATF7IP, proposed gene TGCT1 on Xq27, and gr/gr deletion in the AZFc region on Y-chromosome [11] [12] [13] [14] [15] [16] [17] [18] . Many of the loci identified on GWAS are directly involved in the KIT-KITLG signaling cascade, confirming the central role of this pathway in TGCT tumorigenesis.
TGCT development is a polygenic, multistep process; initial events occur in the embryo stage of development, followed by dormancy until puberty wherein hormonal stimulation involved in spermatogenesis results in further genetic events that result in the clinical manifestation of TGCT [19] . TGCTs are histologically divided into seminomas, which resemble primordial germ cells, and NSGCT, which are more undifferentiated (embryonal carcinomas) or differentiated towards embryonic (teratoma) or extra-embryonic (yolk sac or choriocarcinoma) elements [15, 20] . There is support that both histologic variants of TGCT arise from a common pathogenesis, suggested by the finding that about 15% of TGCTs contain both seminomatous and nonseminomatous histologies [21] [22] [23] . Despite their heterogeneity, all TGCTs are believed to arise from intratubular germ cell neoplasia (ITGCN), a precursor lesion often visualized adjacent to invasive TGCT [24] . The genetic landscape of ITGCN is not well established, but KIT mutations are described in some cases [25] .
TESTICULAR GERM CELL TUMOR GENETIC AND EPIGENTIC PROFILES

Chromosomal abnormalities
The genetics of TGCT tend to reflect their embryonic origin, with a generally low incidence of mutations, loss of parental pattern of genomic imprinting, distinct DNA methylation profiles, and frequent uniparental disomies [26] . Seminoma and ITGCN cells are typically hypertriploid, whereas NSGCT cells are typically hypotriploid [27] . Compared to adult solid tumors such as lung, kidney, and bladder that have mutation rates between 8 and 11 mutations/megabase, the mutation frequency of TGCTs is much lower at approximately 0.5 mutations/megabase [28 && ].
Gain of 12p: the only consistent chromosomal abnormality of testicular germ cell tumor The presence of isochromosome 12p [i(12p)] on karyotype analysis in many TGCT specimens was the first reported genetic marker of TGCT [29] . Florescence in situ hybridization (FISH) confirmed extra copies of 12p in virtually all TGCT specimens, becoming a hallmark pathognomonic for TCGT. The exact mechanism through which gain of 12p results in TGCT is unclear, but a number of genes are implicated including the proto-oncogenes cyclin D2 (CCND2) [30] and KRAS [31] , the growth factor receptor TNFRSF1A, GLUT3 (glucose transporter), REA (estrogen receptor), FLJ22028 [32] , NANOG, STELLAR/DPPA3, and GDF3 (stem-cell associated genes) [33] that may result in transformation and maintenance of pluripotency [6] .
Other chromosomal abnormalities A number of karyotypic analyses have uncovered other chromosomal anomalies associated with TGCTs [34, 35] . Increase in copy numbers of chromosomes 7, 8, 17, and X and decreases in copy numbers of chromosomes 4, 11, 13, and 18 are reported [34] .
KEY POINTS
Adult TGCTs have frequent chromosomal anomalies, including ubiquitous gain of isochromosome 12p, and low rates of somatic mutations.
Recent molecular studies have confirmed well-described TGCT-associated genetic mutations (i.e., KIT and KRAS) and also identified novel mutations.
High rates of alterations within the TP53-MDM2 axis are seen in patients with platinum-resistant disease as are potentially actionable targets, including TP53-MDM2, PI3 kinase, and MAPK signaling pathway alterations.
Increasing genomic and epigenomic characterization of TGCT may shed light on the biology of these tumors, including prognosis and mechanisms of cisplatinresistance.
Cytogenetic analysis on 124 microdissected specimens identified nonrandom rearrangements with an association to certain histologies (1p32-36 and 7q11.2 rearrangements associated with teratoma; 1p22 rearrangements associated with yolk-sac tumor) and other clinical characteristics [36] . Genomic studies investigating the clinical significance of i(12p) and other chromosomal abnormalities have generally been plagued by inconsistent results [37] [38] [39] [40] [41] .
Single gene mutations KIT The KIT gene, which encodes a proto-oncogene receptor tyrosine kinase protein and plays crucial roles in cell survival and proliferation, is well characterized in TGCT [42] . A query of the Catalogue of Somatic Mutations in Cancer (COSMIC) database identified KIT mutations in 19% (52/261) of seminomas and just 2% (2/98) of NSGCT, confirming that while rare in nonseminomas, a significant proportion of seminomas harbor KIT mutations [9, 33, 43, 44] . KIT mutations in TCGT pose attractive treatment possibilities in light of highly effective response rates of gastrointestinal stromal tumor (GIST) that harbor KIT mutations to imatinib (Gleevec) [45] . A small phase II study of imatinib in heavily pretreated GCTs demonstrating KITpositivity on immunohistochemical staining failed to demonstrate any response [46] , though imatinibsensitive KIT mutations are reported in TGCTs [47, 48] . Recent next generation sequencing (NGS) efforts identified that most patients with TGCT harbor exon 17 mutations, which are generally imatinib-resistant, emphasizing the need for precise genotyping and potentially explaining the disappointing results of the phase II study [49] .
KRAS/NRAS
KRAS and NRAS are proto-oncogene receptor tyrosine kinase proteins that activate multiple downstream pathways including the Raf/MEK/ERK and PI3 kinase pathways [50] . A query of the COSMIC database indicates KRAS and NRAS mutations in just 5-7% of seminomas and 0% of nonseminomas [33] . RAS mutations and FGFR3 mutations were identified at a higher frequency in chemoresistant vs. sensitive tumors [51] and given the potential clinical relevance of RAS pathway mutations and potential therapeutic approaches [49, 52] , further research is needed to clarify the roles of such mutations in TGCTs.
BRAF
The BRAF gene encodes a serine/threonine kinase that regulates the MAP kinase/ERK pathway and plays an important role in cell proliferation and differentiation [9] . COSMIC query indicates that BRAF mutations are rare in TGCT (1% of seminoma, 2% of nonseminomas) [33, 44] . Honecker et al. [53] compared unselected TGCTs to cisplatin-resistant TGCTs and found a significantly higher incidence of BRAF (V600E) mutations in the resistant vs. sensitive tumors (26 vs. 1%). These findings were not reproduced in a subsequent study in patients with cisplatin-resistant TGCT, where BRAF mutations were not identified though hotspot variants in PIK3CA, AKT1, and FGFR3 were noted [51] . The disparate reported incidence of BRAF mutations highlights the need for further research with contemporary sequencing platforms.
TP53
The TP53 gene encodes p53 -a cell-cycle regulatory protein -that plays an important role in stress response through induction of apoptosis and cellcycle arrest for DNA repair. Loss of p53 function results in lack of cell-cycle regulation and is associated with more aggressive tumors and chemotherapy-resistance [54] [55] [56] . Although TP53 mutations are common in somatic tumors [55] , they are rare in TGCTs, with the COSMIC database finding TP53 mutations in 7% of seminomas (10/148) and 0% of nonseminomas (0/9) [44, 54] . Paradoxically, TGCTs often over-express wild-type p53 [57] [58] [59] though this p53 over-expression may occur in conjunction with the over-expression of various p53 inhibitors, including microRNAs (miRNAs) [60] and the oncoprotein murine double minute 2 (mdm2), which inhibits wild-type p53 through nuclear export and ubiquitination [61] . Researchers have found that interference of mdm2-p53 binding with the small molecule inhibitors RITA and Nutlin-3 rescued the p53 pathway, resulting in cell-cycle arrest and apoptosis in tumor cells, which has exciting treatment implications [62] . The incidence of TP53 pathway mutations, including MDM2 amplifications, was recently reported to be approximately 25% among patients with cisplatin-resistant disease [63] .
The future
The search for genetic alterations with clinical relevance to TGCT is being accelerated by the advent of NGS. Importantly, The Cancer Genome Atlas (TCGA) is conducting an integrative analysis of 150 TGCTs, which will provide comprehensive data on copy number changes, somatic mutation profile, RNA expression, methylation status, and other molecular characteristics of TCGT. To date, whole exome sequencing of 42 TGCT cases demonstrated that in addition to 12p amplification and KIT mutations, recurrent mutations were noted in the tumor suppressor gene CDC27 (11.9%) and copy number analysis demonstrated amplification of the spermatocyte development gene FSIP2 (15.3%) in a 0.4 Mb region at Xq28 (15.3%) [28 && ]. These authors also reported missense mutations in the DNA repair gene XRCC2 in two treatment-resistant tumors, implying that impaired DNA repair may lead to cisplatin-resistance [28 && ]. Another study that performed whole exome sequencing on eight patients with seminoma found a total of 98 novel and distinct gene mutations, in addition to well known KIT and KRAS mutations [64] .
NGS may provide key information for clinical decision-making. In a study of patients with cisplatin-resistant GCT treated with sunitinib, NGS identified a rare RET amplification known to be sensitizing to sunitinib in the lone responder [65] . Recent data suggests that actionable targets may be present in up to 50% of patients with cisplatin-resistant GCT, providing hope that other targeted solutions exist to these difficult clinical challenges [49] .
Active research is ongoing to identify patients who may be at risk for treatment-related toxicities, including infertility, hypogonadism, secondary malignancies, metabolic syndrome, cardiovascular disease, and neurologic toxicity [5] . Certain polymorphisms, including GSTP1, are associated with the development of neurotoxicity though genetic predisposition factors for the development of longterm sequelae of chemotherapy have not been identified for most treatment-related toxicities [66] .
Gene expression profiling
Differential gene expression patterns play a key role in determining the histologic phenotype and biology of the tumor. There are potential pitfalls in interpreting expression data because TGCTs represent a rare tumor; as such, most studies represent a small sample size using different gene array chip technologies and different statistical methods. Furthermore, gene-profiling technology relies on the principle of comparing neoplastic tissue with control tissue, but this highly sensitive technology can be easily contaminated, especially in TGCT wherein normal testicular tissue contains a mixture of cell types and tumors often representing varied histologies [9] .
Nevertheless, several interesting expression findings are reported. Researchers from Memorial Sloan Kettering Cancer Center performed gene expression profiling on NSGCT from cisplatintreated patients to identify a 10-gene model that was independently predictive of survival after clinical risk stratification was included in a multivariate model. Interestingly, genes involved in immune-response pathways were more highly expressed in patients with favorable clinical outcomes, while genes associated with active differentiation were more highly expressed in patients with poorer clinical outcome [67] . As a follow-up, the authors performed comparative genomic hybridization to identify regions associated with survival and then identified individual genes associated with survival but were distinct from their previous expression-only analysis [68 && ]. Certain gene expression levels appear to correlate to cisplatin-resistance. Seladin-1, a multifunctional protein involved in inhibition of apoptosis through regulation of caspase-3, had highest expression in teratoma (considered chemo/radiotherapyresistant), and lowest expressions in chemo/radiotherapy-sensitive seminoma [69] . In another study, three TGCT cell lines made resistant to cisplatin via long-term exposure to the drug had marked increase in CCND1 expression, a cell cycle regulatory gene implicated in cisplatin-resistance [70] . Other gene expression patterns and transcriptome sequencing (complete set of RNA transcripts produced) show promising early results in differentiating metastatic from nonmetastatic tumors [71, 72] .
Epigenetics
Epigenetic modifications to DNA or associated proteins are recognized to play a role in the development of many malignancies, including TGCT development and are associated with chemotherapy resistance [73] . There are three main epigenetic mechanisms identified: DNA promoter methylation, chromatin remodeling, and miRNA regulation [74] . Although chromatin remodeling and miRNA analyses are nascent for TGCTs, DNA promoter methylation differences are more extensively studied in TGCTs [75] . Seminomas are extensively hypomethylated compared with nonseminomas, which show higher DNA methylation frequencies on the level of other solid tumors [76] [77] [78] .
In NSGCT patients, Koul et al. [79] found that RASSF1A and HIC1 promoter hypermethylation was associated with cisplatin-resistance, whereas MGMT and RARB promoter hypermethylation was associated with cisplatin sensitivity. Furthermore, cisplatin treatment appeared to induce de-novo promoter hypermethylation in vivo, potentially explaining acquired cisplatin-resistance in some patients [79] . Cheung et al. [80] studied the DNA methylation profile of six embryonal carcinomas and identified 40 genes/noncoding RNAs with hypermethylated promoters, including several sex-linked genes and RBMY1A, a testis-specific gene for spermatogenesis not previously implicated in TGCT. Honecker et al. [53] reported promoter methylation of hMLH1 and resultant reduced protein expression was associated cisplatin-resistance. In a provocative study, Wermann et al. [81] demonstrated a relationship between 5-methyl cystosine and chemotherapy sensitivity in TGCT whereby cisplatin-resistant seminomas showed a hypermethylated pattern not otherwise noted in seminomas. Furthermore, a cell line from this tumor specimen demonstrated cisplatin sensitivity after demethylation with 5-azacytidine [81] .
Although the functions of the majority of miRNAs that regulate gene expression are yet to be elucidated, miRNA-372 and miRNA-373 are identified to suppress the p53 pathway in TGCTs, allowing cellular proliferation in the presence of wild-type p53 [82] . miRNA 449a and 449b, which are believed to suppress cell proliferation through various p53 dependent and independent mechanisms, are decreased in TGCT specimens compared with normal testes [83] . Promoter hypermethylation of miRNA 199a has been implicated in the upregulation of PODXL, an antiadhesion protein expressed in TGCT and implicated in development of invasiveness and metastasis [84] .
Cellular differentiation can occur through epigenetic alterations, and TGCTs are no different. The pluripotency and transcription factor Oct4 appears to play an important role in maintaining an apoptotic response to DNA damage [85] . The relationship between Oct4 and cisplatin responsiveness is complex and several studies show no direct correlation with Oct4 expression and treatment response [86, 87] .
CONCLUSION
TGCT development is a complex, multistep process that likely begins in utero during the embryo stage with GWAS identifying a strong inheritable component. The precursor lesion to invasive tumors is ITGCN, which has not been thoroughly genetically characterized but likely involves KIT/KITLG signaling in a proportion of patients. Although believed to have a common etiology, precursor lesion (ITGCN), and chromosomal aberration profile (gain of 12p), modern genetic analyses demonstrate significant differences between tumor types that are currently being investigated to explain their distinct biology and provide clues in responsiveness to treatment. Broad chromosomal abnormalities are features of TCGT while somatic mutation rates are low and recurrent mutations are infrequent. Mechanisms of cisplatin-resistance are not well characterized but our understanding is increasing with large-scale sequencing efforts. Molecular characteristics of TCGT are currently not used for predicting clinical behavior or response to treatment. Nevertheless, while still in the early phases, elucidation of the genetic and epigenetic characteristics of TGCT will very likely have significant clinical implications regarding prevention, treatment strategy, and prognosis.
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